Longitude Capital United States

Longitude Capital is a private equity group founded in 2006 with offices in Menlo Park, California and Greenwich, Connecticut. The firm has $700 million in assets and has raised two funds, with the most recent fund closing at $385m in 2012. Longitude makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. Longitude Capital primarily invests in North America and the European Union but may also consider opportunities in the Middle East.

Year Founded
2006
Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Mark Chin

Lumira Capital

Lumira Capital is a Venture Capital firm that changed its name from MDS Capital In 2007 and have been investing in companies since 1989. The firm is based in Toronto will additional offices in Boston and Montreal. The firm currently manages 2 funds for a total of approximately $180 million in assets under management. The firm’s Lumira Capital II fund currently hold approximately $115 million in assets and is looking to invest in companies across North America. The firms Merck Lumira Biosciences fund formed via a partnership with Merck Serano, currently holds around $65 million in assets and is looking for early stage opportunities in companies located in or looking to move to Quebec. The firm typically makes initial investments ranging from $2-$5 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm plans to make 4-6 investments over the next 6-9 months.

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Peter Van Der Velden
Managing General Partner 
Jacki Jenuth
Vice President 
Brian Underdown
Managing Partner 
Beni Rovinski
Managing Partner 

Lymo Investments

Lymo Investments is a multi-family venture fund based in Silicon Valley, CA. The firm is an active investor in the medical device sector, and is interested in opportunities worldwide. Initial investments are typically about $50,000 with the potential for follow-on investments totaling $500,000, and may be structured as equity or as debt. Lymo Ventures does not invest in seed rounds. In the recent past Lymo Investments has allocated new investments at a rate of approximately one every two months. The firm offers support and expertise to portfolio companies but does not seek a board seat.

Norm Gitis
Founder 

M.H. Carnegie & Co.

M.H. Carnegie & Co. founded in 21 is a venture capital and private equity firm based in Sydney Australia. The currently has about $2 million in committed capital across several funds. The firm invests in several sectors including the Life Sciences. The firm can make early to late stage investments typically allocating USD 2-5 million per company. The firm is currently interested in companies abroad that plan to set up operations in Australia as the firm is mandated to invest in Australian-based companies. The firm plans to make 2-3 new investments in the next 12 months and is actively seeking new opportunities.
Mark Carnegie
Principle 
Trevor Moody
Principle 

Mayo Clinic Ventures

Mayo Clinic Ventures serves to commercialize Mayo Clinic technologies for the benefit of patients worldwide while generating revenue to support clinical practice, research and education at Mayo Clinic. The office has licensed hundreds of technologies in the fields of medical devices, diagnostics, therapeutics, and healthcare IT, and has focused efforts in technology-based ventures and start-ups.  Mayo Clinic Ventures also has a $20M venture capital fund which is used to spin out companies that are developing products based on Mayo Clinic research.

Kelly Krajnik
Business Development Manager 

MBL Venture Capital

MBL Venture Capital founded in 2 is the investment arm of Medical & Biological Laboratories Co. a Japanese biotechnology company and is based in Nagoya Japan with an additional office in Tokyo. The firm primarily makes early stage investments solely in the Life Sciences. The firm recently raised a new fund in March 214 and looks to make about 2-3 new investments in the next 12 months. The firm typically allocates USD 1-2 million per round and up to USD 3 million per company. The firm can invest globally with particular interests in the USA and Europe. The firm is actively seeking new investment opportunities.
Masako Hashimoto
Senior Manager 

Med Qiao Group LLC United States

Jean Yao, PhD, with 20+ years of extended experience in the areas of biology, medical research, and medical industry, has held various positions at Mayo Clinic and University of Minnesota. She funded Med Qiao Group LLC as for the Bridge between US and China in life science. Med Qiao provides business consulting services that include investment funding, market analysis, intellectual property protection, clinical trial arrangement, product approval application, China branch or division establishment as well as marketing, promotion, distribution and onsite manufacturing of medical products.

Jean Yao
Managing Partner 

MedForce

MedForce is the business accelerator arm of Almond Tree Capital and is based in Davis CA. The program makes seed and venture round investments in the form of equity or convertible loans. Investments may range up to $5 with the potential for follow-on investments. While Medforce?s investments are not restricted by region MedForce prefers to support companies based in Northern California or with ties to the region. The fund plans to invest in 2-4 companies in the next 6-9 months.
Cary Adams
CEO 
Christian Renaudin
Partner 

MedPro Investors

MedPro Investors is a group of accredited investors based in New York USA. The group is made up of over 1 healthcare professionals seeking to invest in technologies that significantly advance the standard of care. The group considers companies at a range of stages and is geographically agnostic. Since the members are investing their own capital the investment size and capital structure are highly flexible. The group is actively seeking new investment opportunities and is open to leading financing rounds.
Stephen Nagler
Executive Director 

Medtronic United States

Medtronic was founded in 1949 and is based in Minneapolis Minnesota. Medtronic makes strategic investments and acquisitions in the medical device sector and is focused on cardiovascular diseases diabetes diseases of the nervous system (including Parkinson's disease and dystonia) and musculoskeletal conditions. The firm has acquired a number of medical technology and biotechnology companies. Medtronic is also interested in orthopedic products sports health products and telehealth/connected medical devices (particularly consumer apps for health management). Medtronic also makes grants to non-profit organizations. Instructions on applying for investment or grants can be found at Innovate With Medtronic: http://www.medtronic.com/innovation/innovate-with-medtronic.html

Conrad Wang
Senior Director Corporate Development 
Lawrence Cho
Senior Director, Corporate Strategy & Business Development